For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News
Read all about the latests in HIV/Aids research and treatment protocols and also developments made into various specific components of managing this disease that is by itself also evolving.
Source: USFDA & Staff Writer, TMN Jul 19, 2018 6 years ago
A small percentage of patients, some of whom have taken many HIV drugs in the past, have multidrug-resistant HIV, limiting their treatment options
HIV naturally mutates and eventually develops resistance to ARVs, which are then rendered ineffective. Patients infected with drug resistant strains of HIV are therefore commonly moved to alternative regimens known as 2nd line drugs.
&n...
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from mild dizziness to life-threatening liver damage. However, if they stop taking the drugs, the virus hiding inside their cells can spontaneously resurface.
In fact...
Source: University of Edinburgh Jul 21, 2018 6 years ago
People infected with HIV are twice as likely to suffer from heart disease, research has found.
Analysis of global figures reveals that HIV-associated cardiovascular disease has more than tripled in the past 20 years as more people are living longer with the virus.
The greatest impact is in sub-Saharan Africa and Asia Pacific regions, with Swaziland, Botswana and Lesotho particularly ...
French biotech Abivax’s might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.
The company has announced results from the first group of patients in its most recent phase 2a trial testing the potential HIV cure treatment codenamed ABX464.
The study aimed at acc...